Oragenics Inc/ US6840235005 /
30/08/2024 21:59:48 | Chg. +0.11 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.25USD | +9.21% | 12,666 Turnover: 15,899.72 |
-Bid Size: - | -Ask Size: - | 1.29 | 1.12 |
GlobeNewswire
21/08
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation ...
GlobeNewswire
16/08
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYS...
GlobeNewswire
14/08
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wid...
GlobeNewswire
12/08
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
GlobeNewswire
08/08
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity T...
GlobeNewswire
16/05
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
GlobeNewswire
07/05
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
GlobeNewswire
01/09/2020
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developm...
GlobeNewswire
14/07/2020
Recce Pharmaceuticals Adds Biotech Veteran Alan W. Dunton M.D. to its Board of Directors
GlobeNewswire
30/04/2019
Investor Expectations to Drive Momentum within H&R Block, Aercap Holdings N.V, Oragenics, and Atomer...
GlobeNewswire
20/06/2018
Diamond Equity Research Initiates Coverage on Oragenics Inc. (NYSE:OGEN) with a Valuation of $3.50 P...